178 related articles for article (PubMed ID: 30825968)
1. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
Brunner TB; Blanck O; Lewitzki V; Abbasi-Senger N; Momm F; Riesterer O; Duma MN; Wachter S; Baus W; Gerum S; Guckenberger M; Gkika E
Radiother Oncol; 2019 Mar; 132():42-47. PubMed ID: 30825968
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
Gkika E; Hallauer L; Kirste S; Adebahr S; Bartl N; Neeff HP; Fritsch R; Brass V; Nestle U; Grosu AL; Brunner TB
BMC Cancer; 2017 Nov; 17(1):781. PubMed ID: 29162055
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
4. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.
Tao R; Krishnan S; Bhosale PR; Javle MM; Aloia TA; Shroff RT; Kaseb AO; Bishop AJ; Swanick CW; Koay EJ; Thames HD; Hong TS; Das P; Crane CH
J Clin Oncol; 2016 Jan; 34(3):219-26. PubMed ID: 26503201
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review.
Lee J; Yoon WS; Koom WS; Rim CH
Strahlenther Onkol; 2019 Feb; 195(2):93-102. PubMed ID: 30206644
[TBL] [Abstract][Full Text] [Related]
6. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
Feng M; Suresh K; Schipper MJ; Bazzi L; Ben-Josef E; Matuszak MM; Parikh ND; Welling TH; Normolle D; Ten Haken RK; Lawrence TS
JAMA Oncol; 2018 Jan; 4(1):40-47. PubMed ID: 28796864
[TBL] [Abstract][Full Text] [Related]
7. Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma.
Zhang XX; Ma HB; Li TH; Huang B; Jia NY; Meng Y
Clin Transl Oncol; 2023 Mar; 25(3):731-738. PubMed ID: 36401766
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma.
Barney BM; Olivier KR; Miller RC; Haddock MG
Radiat Oncol; 2012 May; 7():67. PubMed ID: 22553982
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience.
Polistina FA; Guglielmi R; Baiocchi C; Francescon P; Scalchi P; Febbraro A; Costantin G; Ambrosino G
Radiother Oncol; 2011 May; 99(2):120-3. PubMed ID: 21621289
[TBL] [Abstract][Full Text] [Related]
11. Repeated SBRT for in- and out-of-field recurrences in the liver.
Gkika E; Strouthos I; Kirste S; Adebahr S; Schultheiss M; Bettinger D; Fritsch R; Brass V; Maruschke L; Neeff HP; Lang SA; Nestle U; Grosu AL; Brunner TB
Strahlenther Onkol; 2019 Mar; 195(3):246-253. PubMed ID: 30353350
[TBL] [Abstract][Full Text] [Related]
12. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
13. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
[TBL] [Abstract][Full Text] [Related]
14. Limitations of conventional doses of chemoradiation for unresectable biliary cancer.
Crane CH; Macdonald KO; Vauthey JN; Yehuda P; Brown T; Curley S; Wong A; Delclos M; Charnsangavej C; Janjan NA
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):969-74. PubMed ID: 12095564
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy.
Dewas S; Bibault JE; Mirabel X; Fumagalli I; Kramar A; Jarraya H; Lacornerie T; Dewas-Vautravers C; Lartigau E
Radiat Oncol; 2012 Oct; 7():166. PubMed ID: 23050794
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic ablative radiotherapy for patients with unresectable or medically inoperable cholangiocarcinoma.
Liu MY; Lo CH; Lin CS; Chao HL; Yang JF; Lin KT; Fan CY; Su YF; Huang WY
Tumori; 2017 May; 103(3):236-241. PubMed ID: 28058710
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
Kopek N; Holt MI; Hansen AT; Høyer M
Radiother Oncol; 2010 Jan; 94(1):47-52. PubMed ID: 19963295
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
19. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients.
Zeng ZC; Tang ZY; Fan J; Zhou J; Qin LX; Ye SL; Sun HC; Wang BL; Li D; Wang JH; Zeng MS; Guo W; Tan YS
Cancer J; 2006; 12(2):113-22. PubMed ID: 16630402
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma.
Elganainy D; Holliday EB; Taniguchi CM; Smith GL; Shroff R; Javle M; Raghav K; Kaseb A; Aloia TA; Vauthey JN; Tzeng CD; Herman JM; Koong AC; Krishnan SX; Minsky BD; Crane CH; Das P; Koay EJ
Cancer Med; 2018 Oct; 7(10):4880-4892. PubMed ID: 30152073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
